{"id":"prasugrel-bivalirudin","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Dyspnea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Prasugrel is a P2Y12 platelet receptor antagonist that irreversibly inhibits platelet aggregation, while bivalirudin is a direct thrombin inhibitor that prevents thrombin-mediated coagulation. Together, they provide complementary antithrombotic effects—prasugrel blocks platelet activation and aggregation, and bivalirudin inhibits the coagulation cascade—reducing thrombotic complications in acute coronary syndromes.","oneSentence":"Prasugrel and bivalirudin are combined to provide dual antiplatelet and anticoagulant activity for acute coronary syndrome management.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:02:06.805Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome (ACS) in patients undergoing percutaneous coronary intervention (PCI)"}]},"trialDetails":[{"nctId":"NCT02618837","phase":"PHASE4","title":"Downstream Versus Upstream Strategy for the Administration of P2Y12 Receptor Blockers","status":"UNKNOWN","sponsor":"University of Padova","startDate":"2015-12-14","conditions":"Unstable Angina or Non ST Elevated Myocardial Infarction","enrollment":2520},{"nctId":"NCT01789814","phase":"PHASE4","title":"Effect of Prasugrel Versus Clopidogrel on Platelet Function After Bivalirudin Cessation","status":"COMPLETED","sponsor":"Tufts Medical Center","startDate":"2013-07","conditions":"Coronary Artery Disease","enrollment":24},{"nctId":"NCT01510171","phase":"PHASE4","title":"Rapid Activity of Platelet Inhibitor Drugs Study","status":"COMPLETED","sponsor":"Careggi Hospital","startDate":"2012-01","conditions":"ST-segment Elevation Myocardial Infarction","enrollment":50},{"nctId":"NCT01805570","phase":"PHASE4","title":"Rapid Activity of Platelet Inhibitor Drugs Study 2","status":"COMPLETED","sponsor":"David Antoniucci","startDate":"2012-11","conditions":"Myocardial Infarction","enrollment":50},{"nctId":"NCT00976092","phase":"PHASE4","title":"Efficacy Study of Combined Prasugrel and Bivalirudin Versus Clopidogrel and Heparin in Myocardial Infarction","status":"UNKNOWN","sponsor":"Deutsches Herzzentrum Muenchen","startDate":"2009-09","conditions":"Myocardial Infarction","enrollment":548},{"nctId":"NCT01160900","phase":"PHASE3","title":"FIT (Fast Infarction Treatment): Complete Revascularization During Primary Percutaneous Coronary Intervention (PCI) Can be Achieved Safely With an Improved Clinical Outcome During the Indexed Hospitalization.","status":"UNKNOWN","sponsor":"Azienda Ospedaliera San Camillo Forlanini","startDate":"2010-07","conditions":"Myocardial Infarction, Ischemia, Heart Failure","enrollment":180},{"nctId":"NCT01158846","phase":"PHASE4","title":"Bivalirudin/Prasugrel Versus Abciximab/Clopidogrel in Patients Presenting With STEMI","status":"UNKNOWN","sponsor":"I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio","startDate":"2010-08","conditions":"ST-Elevation Myocardial Infarction, Primary Percutaneous Coronary Intervention","enrollment":800}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Efient","Angiox"],"phase":"marketed","status":"active","brandName":"prasugrel/bivalirudin","genericName":"prasugrel/bivalirudin","companyName":"I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio","companyId":"i-r-c-c-s-ospedale-galeazzi-sant-ambrogio","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Prasugrel and bivalirudin are combined to provide dual antiplatelet and anticoagulant activity for acute coronary syndrome management. Used for Acute coronary syndrome (ACS) in patients undergoing percutaneous coronary intervention (PCI).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}